Mukesh Ratnaparkhi | Pharmacology | Best Researcher Award

Published on by Best Paper Awards

Dr. Mukesh Ratnaparkhi | Pharmacology | Best Researcher Award 

Professor | Marathwada Mitramandals College of Pharmacy | India

Dr. Mukesh P. Ratnaparkhi, a distinguished pharmaceutical scientist with over 19 years of academic and research experience, demonstrates strong suitability for a Best Researcher Award through his extensive contributions to pharmaceutics, drug delivery systems, and formulation science. Currently serving as a Professor in Pharmaceutics at Marathwada Mitra Mandal’s College of Pharmacy, Pune, he has progressed through roles of increasing responsibility and is an approved Associate Professor, postgraduate teacher, and Ph.D. research guide under Savitribai Phule Pune University. His academic foundation includes a Ph.D. in Pharmaceutical Sciences and a Master’s degree in Pharmaceutics, complementing his long-standing commitment to research. Dr. Ratnaparkhi has an impressive research portfolio with 74 publications in reputed Scopus, Web of Science, UGC Care, and international indexed journals, addressing critical pharmaceutical challenges such as solubility enhancement, nanoformulations, targeted pulmonary delivery, nasal drug delivery, and advanced drug dispersion techniques. His work spans nanosponge systems, nanoemulgels, cubosomes, solid dispersions, and dry powder inhalation formulations, signifying his expertise in innovative and translational drug delivery approaches. He holds four patents (three granted and one filed), demonstrating originality and innovation, and has guided or collaborated on numerous research projects. Complementing his publication record, he has delivered 31 scientific presentations at national and international conferences, showcasing the continued relevance and impact of his research. His professional strengths include excellent communication, leadership, team management, and a strong research orientation, supported by early industrial training that broadened his practical understanding of pharmaceutical processes. With nearly two decades of academic service, consistent research productivity, significant innovation, mentorship roles, and contributions that influence modern drug delivery systems, Dr. Ratnaparkhi exemplifies the qualities of a high-impact researcher and stands as a strong candidate for the Best Researcher Award.

Profiles: Google Scholar | ORCID | Scopus | ResearchGate | LinkedIn

Featured Publications

  1. Ratnaparkhi, M. P., & Suryawanshi, A. N. (2025). Development and characterization of novel cilnidipine-loaded nanosponge formulations. International Journal of Drug Delivery Technology, 15(3), 1198–1204.

  2. Kshirsagar, S. D., & Ratnaparkhi, M. (2025). Formulation and evaluation of propolis loaded nanosponges based topical anti-inflammatory gel. Indian Journal of Pharmaceutical Education and Research, 59(4), 1–11.

  3. Tekade, A., Ratnaparkhi, M., Shewale, A., Shinde, R., Kulkarni, G., & Pawar, P. (2025). Design and assessment of in situ nasal gel incorporated with nanostructured cubosomes for the targeted therapy of schizophrenia. Journal of Research in Pharmacy, 29(3), 947–958.

  4. Ratnaparkhi, M., Binawade, B., Salvankar, S., Aswar, M., Jadhav, P., Parhad, P., Bhangare, S., & Dalvi, S. (2025). Intravaginal administration of metformin HCl loaded nanoemulgel for treatment of PCOS: In-vitro and in-vivo study. Brazilian Journal of Pharmaceutical Sciences.

  5. Ratnaparkhi, M. P., Tekade, A. R., Salvankar, S. S., Dalvi, S. D., Kulkarni, G. M., & Markand, M. G. (2025). RP-HPLC method development and validation for the quantification of remdesivir IV formulation. Indian Drug, 62(6), 45–49.

Dr. Ratnaparkhi’s research advances innovative drug-delivery systems that enhance therapeutic efficiency and patient outcomes. His work contributes to modern pharmaceutical science by translating nanotechnology-based formulations into practical healthcare solutions with global impact.

Dong-Joon Oh | Pharmaceutical Formulation | Best Researcher Award

Published on by Best Paper Awards

Mr. Dong-Joon Oh | Pharmaceutical Formulation | Best Researcher Award

Director, Research & Development Division at Han Wha Pharma Co., Ltd, South Korea.

Dong-Joon Oh is an accomplished R&D leader in the pharmaceutical industry, with deep expertise in formulation development, regulatory affairs, and clinical research strategies. Known for his cross-functional leadership and innovation in drug repositioning and modified-release systems, Mr. Oh has contributed to the development and approval of numerous generic and platform-based products. His strategic insight and successful collaborations with global partners continue to shape advancements in pharmaceutical technology and regulatory excellence. He is currently pursuing a Ph.D. in Pharmacy at Yonsei University while leading R&D initiatives at Han Wha Pharma Co., Ltd.

Publication Profile

Scopus 

Education

Mr. Dong-Joon Oh is currently pursuing a Ph.D. in Pharmacy at Yonsei University, South Korea, with an expected completion date in January 2026. He holds a Master of Science degree in Chemical Engineering (2007) and a Bachelor of Science in Nano Life Science and Chemical Engineering (2005), both from Hannam University, Daejeon, South Korea. His educational foundation combines strong interdisciplinary training in pharmaceutical sciences, nanotechnology, and chemical engineering.

Professional Experience

Mr. Dong-Joon Oh is a seasoned pharmaceutical R&D expert with over 15 years of industry experience in drug formulation, regulatory submissions, and technology transfer. He currently serves as a senior researcher at Han Wha Pharma Co., Ltd., where he leads R&D strategy, secures government research grants, and coordinates licensing deals with over 20 pharmaceutical companies. His leadership resulted in the successful execution of 15 R&D projects and the advancement of drug repositioning pipelines.

Prior to this, at Hyundai Pharm Co., Ltd. / Bio-innotis, he managed end-to-end development and submission processes for 12 clinical trial dossiers (IND/CTD), earning recognition as Excellent Researcher (2019) and Best Clinical Submission Awardee (2020). At Celltrion Pharm, Inc., he played a pivotal role as Technical Leader (GGP TL) in developing Celltrion’s first FDA-approved generic drug, overseeing 33 formulation launches and pioneering 5 new platform technologies. His early career at Yungjin Pharmaceutical Co., Ltd. involved formulation development, registration of complex APIs, and new drug development, where he was promoted to Project Leader in 2013.

Research Interest 

Mr. Oh’s research focuses on:

  • Pharmaceutical formulation and modified-release technologies

  • Fixed-dose combination (FDC) product development

  • Bioequivalence (BE) and pharmacokinetic (PK) study design

  • Drug repositioning and lifecycle management

  • Regulatory science (IND/CTD preparation for domestic and international markets)

  • Platform R&D and scale-up strategies

  • Technology transfer and translational research in pharmaceutical product commercialization

Author Metrics

  • Years of Experience: 15+ years in pharmaceutical R&D

  • Clinical Dossiers Submitted: 12 IND/CTD submissions

  • Formulations Developed: Over 60, including FDA-approved generics

  • Technology Transfers & Licenses: 8 products transferred to 20+ partners

  • Recognition:

    • Excellent Researcher (2019, Hyundai Pharm)

    • Best Clinical Submission Award (2020, Bio-innotis)

Top Noted Publication

Solubility of Simvastatin and Lovastatin in Mixtures of Dichloromethane and Supercritical Carbon Dioxide

authored by Dong-Joon Oh, Byung-Chul Lee, and Sung-Joo Hwang

published in the Journal of Chemical & Engineering

Year: 2007

Citation: 19

Conclusion

Mr. Dong-Joon Oh is highly suitable for the Best Researcher Award in Pharmaceutical Formulation, particularly in the context of industry-driven innovation, technology transfer, and regulatory excellence. His hands-on achievements in developing 60+ formulations, leading major R&D programs, and achieving global approvals reflect leadership, depth, and impact in pharmaceutical sciences.

To further solidify his candidacy, it is recommended he amplify his academic publication output, increase global scientific engagement, and strengthen innovation visibility through patents or novel technologies. Nonetheless, his profile already places him among top-tier industry researchers with transformative contributions to drug development and commercialization.